Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

ClinicalTrials.gov ID: NCT05952869

Public ClinicalTrials.gov record NCT05952869. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 3:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia.

Study identification

NCT ID
NCT05952869
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
303 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 7, 2023
Primary completion
Apr 6, 2025
Completion
Apr 6, 2025
Last update posted
Feb 23, 2026

2023 – 2025

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Alliance for Multispecialty Research, LLC ( Site 0023) Daphne Alabama 36526
Excel Medical Clinical Trials ( Site 0008) Boca Raton Florida 33434
Advanced Pharma Research ( Site 0007) Cutler Bay Florida 33189
Progressive Medical Research ( Site 0021) Port Orange Florida 32127
Clinical Site Partners LLC, dba CSP Orlando ( Site 0028) Winter Park Florida 32789
Synexus Clinical Research US - Evansville ( Site 0031) Evansville Indiana 47714
Franciscan Physician Network - Indiana Heart Physicians ( Site 0040) Indianapolis Indiana 46237
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0001) Troy Michigan 48098
Velocity Clinical Research at The Pioneer Heart Institute, Lincoln ( Site 0026) Lincoln Nebraska 68506
Jubilee Clinical Research ( Site 0030) Las Vegas Nevada 89106
Wake Forest Baptist Health-Cardiovascular Medicine ( Site 0041) Winston-Salem North Carolina 27157
Velocity Clinical Research, Salt Lake City ( Site 0004) West Jordan Utah 84088
Health Research of Hampton Roads, Inc. ( Site 0020) Newport News Virginia 23606

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05952869, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 23, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05952869 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →